Open-angle Glaucoma Market Size, Share, Industry Analysis and Forecast till 2030
DelveInsight’s Open-angle glaucoma (OAG) – Market Insights,
Epidemiology, and Market Forecast—2030 (7MM) report
delivers an in-depth understanding of the disease, historical, and forecasted
epidemiology as well as the market trends of OAG in the United States, EU5
(Germany, France, Italy, Spain, and the United Kingdom), and Japan.
 |
| Open-angle Glaucoma Market |
Geography Covered
·
The
United States
·
EU5
(Germany, France, Italy, Spain, and the United Kingdom)
·
Japan
Open-angle glaucoma – Disease
Understanding and Treatment Algorithm
Open-angle
glaucoma (OAG) is
a progressive form of glaucoma in which the channel formed between the iris and
the cornea remains open and tissue changes along the channel, which gradually
reduces the drainage of the aqueous humor through the trabecular meshwork of
the eye's anterior chamber. It is the most common form of glaucoma which
accounts for the majority of the glaucoma cases.
OAG is
primarily divided into two subtypes, i.e., Primary OAG and Secondary
OAG. The risk factors of OAG are divided into four categories, general
factors, ocular factors, nonocular factors, and ocular hypertension.
Open-angle glaucoma –
Epidemiology
The
disease epidemiology covered in the report provides historical as well as forecasted
epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total
Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM,
Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM,
Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type-Specific
Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM scenario
of OAG in the 7MM countries covering United States, EU5 countries (Germany,
France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
As per
DelveInsight’s analysis, a higher percentage of diagnosed prevalence of OAG was
observed for females, in comparison to males,
in all the 7MM countries. DelveInsight’s analysts have assessed that the total
prevalent population of Glaucoma in the 7MM was 9,819,080 in
2017. In addition to this, it was also assessed that among those with glaucoma
in the 7MM, more than 8.5 million were diagnosed
with OAG.
Open-angle glaucoma –
Drug Chapters
This
segment of the Open-angle glaucoma (OAG) report encloses the detailed analysis
of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It
also helps to understand the clinical trial details, expressive pharmacological
action, agreements and collaborations, approval and patent details, advantages
and disadvantages of each included drug and the latest news and press releases.
The
treatment and market of OAG are dependent on the class of drugs, like prostaglandin
analogs, beta-blockers, alpha-agonists,
and carbonic anhydrase inhibitors. In emerging
therapies following drugs are there Bimatoprost SR (Allergan), PDP
– 716 (Sun Pharma), Trabodenoson (Inotek
Pharmaceuticals), DE-30A (Santen),
and others.
Prostaglandin
derivatives, beta-blockers, Topical
carbonic anhydrase inhibitors (CAIs), alpha2-adrenergic
receptor agonists and Combination therapies are
the most preferred classes for the treatment of open-angle glaucoma. In the
United States, drugs of this class have been approved in the past few years
like Vyzulta, Xelpros, Travatan Z, and
a few others by the US FDA. Rhopressa which is
marketed in both the US and Europe (Rhokiinsa), has recently
completed the phase II trial in Japan. The company is looking to meet with
Japan’s Pharmaceutical and Medical Devices Agency to discuss these results and
identify the next steps for a phase III program in Japan. Apart from
this, Ube Industries and Santen Pharmaceutical in
Japan developed a famous ophthalmic product known as Omidenepag isopropyl
ophthalmic solution 0.002 %, which is marketed under the name of EYBELIS is a
selective prostaglandin E2 receptor 2 agonist with a non-prostaglandin
structure for the treatment of glaucoma and ocular hypertension.
Open-angle glaucoma –
Market Outlook
The
Open-angle glaucoma (OAG) market outlook of the report helps to build a
detailed comprehension of the historic, current and forecasted trends of the
market by analyzing the impact of current therapies on the market, unmet needs,
drivers and barriers and demand for better technology.
As per the
assessment by DelveInsight’s analysts, it has been observed that the market
size of OAG was observed to be USD 3,316.71 million in 2017,
in the 7MM. Among all the seven major markets, the United States covers the
major market share that accounts for 41.01% of the
7MM. In 2017, the market size was accessed to be USD 1,360.30
million in the country.
The
products which are anticipated to be launched in the 7MM include Bimatoprost
SR (Sustained-Release; Allergan), DE-117 (omidenepag
isopropyl; Santen Pharmaceutical); PRO-122 (Laboratorios
Sophia); PDP – 716 (Brimonidine; Sun Pharma); Sepetaprost (DE-126/ONO-9054:
Santen/Ono Pharmaceutical); NCX 470 (Nicox
Ophthalmics) and Nyxol (Phentolamine Mesylate:
Ocuphire Pharma). However, in addition to this, it is anticipated that Aerie
Pharma with its two products ROCKLATAN and RHOPRESSA/Rhokiinsa will
definitely show an impact on the open-angle glaucoma market of Europe.
Recently, in November 2019, the European Commission (EC) granted marketing
authorization to Rhokiinsa 0.02% for the reduction
of elevated intraocular pressure in adult patients with primary open-angle
glaucoma or ocular hypertension.
Besides
this Sun Pharma Advanced Research Company (SPARC) is
also expecting the launch of its product PDP
– 716 (Brimonidine). In addition to this, a product named), DE-130A (of
Santen Pharmaceutical is also anticipated to be launched in the European
countries. ROCKLATAN and RHOPRESSA are
approved in the US and recently Aerie pharma received a positive opinion from
the CHMP. This positive opinion will help in the smooth launch of RHOPRESSA (under the
name RHOKIINSA).
Some of
these products have completed the late clinical stages of development, while
others are in ongoing late clinical development stages. These drug candidates
have shown very promising results and it has been anticipated by DelveInsight’s
analysts that completion of clinical development and launch of these products
in the market, might increase the market share of these companies, and besides
this, patients of OAG will have better management practices.
Open-angle glaucoma
(OAG) – Drugs Uptake
This
section focusses on the rate of uptake of the potential drugs recently launched
in the market or will get launched in the market during the study period from
2017 to 2030. The analysis covers market uptake by drugs; patient uptake by
therapies and sales of each drug.
The
current therapeutic landscape of advanced stage OAG in the 7MM is driven by
several approved therapies, including those with generic products. Of this,
majority of the market share is accommodated by Prostaglandin analogs
generating USD 1,806.12 million, followed by Carbonic
anhydrase inhibitors generating USD 578.42 million while
Miotics contributed the least towards the market share, with USD
146.31 million.
To meet
the unmet need of the market and to provide better versions of current
treatment practices, several companies have shifted their focus toward this
therapeutic area, and several therapies are expected to enter the treatment
market of OAG during our forecast period, including In emerging therapies
following drugs are there Bimatoprost SR (Allergan), PDP
– 716 (Sun Pharma.), DE-130A (Santen),
and others.
Key Benefits
·
This
DelveInsight report will help to develop Business Strategies by understanding
the trends shaping and driving Open-angle glaucoma market
·
Organize
sales and marketing efforts by identifying the best opportunities for
Open-angle glaucoma market
·
To
understand the future market competition in the Open-angle glaucoma market.
Comments
Post a Comment